Effects of daily versus weekly teriparatide for medication‐related osteonecrosis of the jaw: A case–control study

American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaw – 2022 Update

(2022) Salvatore L. Ruggiero et al.   JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY

Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases

(2021) Peter Burckhardt et al.   JOURNAL OF BONE AND MINERAL RESEARCH

A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05

(2021) H. Hagino et al.   OSTEOPOROSIS INTERNATIONAL

Effective ancillary role and long-term course of daily or weekly teriparatide treatment on refractory medication-related osteonecrosis of the jaw: a clinical case series

(2021) Daigo Yoshiga et al.   BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY

Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons

(2021) Jin-Woo Kim et al.   Journal of Bone Metabolism

Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial

(2020) Ie-Wen Sim et al.   JOURNAL OF CLINICAL ONCOLOGY

The role, efficacy and outcome measures for teriparatide use in the management of medication-related osteonecrosis of the jaw

(2020) M. Anabtawi et al.   INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY

Short-Term Teriparatide and Recombinant Human Bone Morphogenetic Protein-2 for Regenerative Approach to Medication-Related Osteonecrosis of the Jaw: A Preliminary Study

(2017) Junho Jung et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Does the Addition of Bone Morphogenetic Protein 2 to Platelet-Rich Fibrin Improve Healing After Treatment for Medication-Related Osteonecrosis of the Jaw?

(2017) Jung-Hyun Park et al.   JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY

Frequency of Teriparatide Administration Affects the Histological Pattern of Bone Formation in Young Adult Male Mice

(2016) Tomomaya Yamamoto et al.   ENDOCRINOLOGY

Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings

(2015) H. Kakehashi et al.   INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY

PTH Promotes Bone Anabolism by Stimulating Aerobic Glycolysis via IGF Signaling

(2015) Emel Esen et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial

(2015) Benjamin Z Leder et al.   LANCET

Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk

(2012) Toshitaka Nakamura et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Parathyroid Hormone Applications in the Craniofacial Skeleton

(2012) H.L. Chan et al.   JOURNAL OF DENTAL RESEARCH

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

(2011) F. Saad et al.   ANNALS OF ONCOLOGY

Molecular Pathways: Osteoclast-Dependent and Osteoclast-Independent Roles of the RANKL/RANK/OPG Pathway in Tumorigenesis and Metastasis

(2011) W. C. Dougall   CLINICAL CANCER RESEARCH